CN104958286B - 用于治疗疾病的化合物 - Google Patents

用于治疗疾病的化合物 Download PDF

Info

Publication number
CN104958286B
CN104958286B CN201510244522.0A CN201510244522A CN104958286B CN 104958286 B CN104958286 B CN 104958286B CN 201510244522 A CN201510244522 A CN 201510244522A CN 104958286 B CN104958286 B CN 104958286B
Authority
CN
China
Prior art keywords
compound
use according
dosage form
epo
hydrazide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201510244522.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104958286A (zh
Inventor
A.库宾
P.福特穆勒
G.沃尔伯
D.舒斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Planta Naturstoffe Vertriebsges M B H
Original Assignee
Planta Naturstoffe Vertriebsges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Planta Naturstoffe Vertriebsges M B H filed Critical Planta Naturstoffe Vertriebsges M B H
Publication of CN104958286A publication Critical patent/CN104958286A/zh
Application granted granted Critical
Publication of CN104958286B publication Critical patent/CN104958286B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201510244522.0A 2010-01-29 2011-01-28 用于治疗疾病的化合物 Expired - Fee Related CN104958286B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA122/2010 2010-01-29
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
CN201180016552.6A CN102858329B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180016552.6A Division CN102858329B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Publications (2)

Publication Number Publication Date
CN104958286A CN104958286A (zh) 2015-10-07
CN104958286B true CN104958286B (zh) 2018-01-05

Family

ID=43707937

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510244522.0A Expired - Fee Related CN104958286B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物
CN201180016552.6A Expired - Fee Related CN102858329B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180016552.6A Expired - Fee Related CN102858329B (zh) 2010-01-29 2011-01-28 用于治疗疾病的化合物

Country Status (12)

Country Link
US (1) US20130065962A1 (enExample)
EP (2) EP2528595B1 (enExample)
JP (1) JP5788907B2 (enExample)
KR (1) KR20120128644A (enExample)
CN (2) CN104958286B (enExample)
AT (1) AT509045B1 (enExample)
AU (1) AU2011208939B2 (enExample)
BR (1) BR112012018772A2 (enExample)
CA (1) CA2788326A1 (enExample)
MX (1) MX2012008815A (enExample)
SG (1) SG182786A1 (enExample)
WO (1) WO2011091461A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013302177A1 (en) * 2012-08-10 2015-03-26 Mcmaster University Antibacterial inhibitors
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents
JP2024511825A (ja) * 2021-03-31 2024-03-15 シェブロン・オロナイト・カンパニー・エルエルシー 低速でのプレイグニッション事象を軽減するための組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088199A (zh) * 1992-07-15 1994-06-22 霍夫曼-拉罗奇有限公司 N-取代的苯胺
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
CN101203522A (zh) * 2005-05-12 2008-06-18 遗传工程与生物技术中心 抗肿瘤化合物及其药物组合物
US20090105233A1 (en) * 2006-09-01 2009-04-23 Chua Peter C Serine-threonine protein kinase and parp modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
DK0581904T3 (da) 1991-04-01 1997-12-29 Univ Duke Fremgangsmåde til inhibering af fibrose
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
CA2344053C (en) * 1998-09-15 2007-04-03 Korea Research Institute Of Bioscience And Biotechnology Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
MXPA01012036A (es) 1999-05-28 2002-05-06 Cheil Jedang Corp Derivados de catecol hidrazona su proceso de preparacion y composicion farmaceuticamente que los contiene.
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
AU2003214534B2 (en) 2002-04-08 2006-08-31 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
JP2006523196A (ja) 2003-03-11 2006-10-12 ニューロサーチ、アクティーゼルスカブ 新規ｋｃｎｑチャネルを調節する化合物及びその医薬用途
ES2523017T3 (es) 2004-03-03 2014-11-20 Glaxosmithkline Llc Derivados de anilina como moduladores selectivos de los receptores de andrógenos
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2427416B1 (en) * 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088199A (zh) * 1992-07-15 1994-06-22 霍夫曼-拉罗奇有限公司 N-取代的苯胺
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
CN101203522A (zh) * 2005-05-12 2008-06-18 遗传工程与生物技术中心 抗肿瘤化合物及其药物组合物
US20090105233A1 (en) * 2006-09-01 2009-04-23 Chua Peter C Serine-threonine protein kinase and parp modulators

Also Published As

Publication number Publication date
AT509045A4 (de) 2011-06-15
KR20120128644A (ko) 2012-11-27
BR112012018772A2 (pt) 2016-04-12
JP2013518061A (ja) 2013-05-20
CN104958286A (zh) 2015-10-07
JP5788907B2 (ja) 2015-10-07
CN102858329A (zh) 2013-01-02
EP2528595A1 (de) 2012-12-05
EP2965755A1 (de) 2016-01-13
MX2012008815A (es) 2012-11-23
CA2788326A1 (en) 2011-08-04
CN102858329B (zh) 2015-06-17
AT509045B1 (de) 2011-06-15
US20130065962A1 (en) 2013-03-14
WO2011091461A1 (de) 2011-08-04
SG182786A1 (en) 2012-09-27
AU2011208939B2 (en) 2015-07-09
AU2011208939A1 (en) 2012-08-30
EP2528595B1 (de) 2015-08-05

Similar Documents

Publication Publication Date Title
US20220001014A1 (en) Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
Li et al. Microglia in neuroimmunopharmacology and drug addiction
BRPI0509282A (pt) compostos contendo hidrazida inibidores de cftr e seus usos
JP2010505774A (ja) 低体温誘導薬剤の使用方法
CN116726178A (zh) sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用
US20230210807A1 (en) Use of benzoate compound in treatment of sars-cov-2 infections
US8410068B2 (en) Compounds for the treatment or alleviation of edema, and methods for their use
CN104958286A (zh) 用于治疗疾病的化合物
Tan et al. Estimated doses of melatonin for treating deadly virus infections: Focus on COVID-19
CN107530316A (zh) 用于预防和治疗胰腺炎、含基于萘醌的化合物作为有效成分的组合物
Lee et al. SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast‐like synoviocytes and mice with collagen‐induced arthritis
MD4802C1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
US20260069578A1 (en) Treatment of neutrophilic dermatoses
Chen et al. Oseltamivir Phosphate Modulates CD24‐Siglec‐G/10 Interaction to Suppress Microglial‐Driven Neuroinflammation After Cardiac Arrest
WO2018057933A1 (en) Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes
CN119632984B (zh) 蝙蝠葛苏林碱在制备髓过氧化物酶抑制剂及治疗急性肺损伤药物中的应用
US20180086827A1 (en) Therapeutics and methods of treating fibroproliferative diseases
KR101844828B1 (ko) 시남알데하이드 유도체를 포함하는 비만 세포 활성화 억제용 조성물
Durán et al. Melatonin: What Do We Know so Far about the Activity of This Hormone against COVID-19?
HK40114082A (en) Novel benzene derivative and immunosuppression-related use thereof
CN101014369A (zh) 利用cox—2选择性抑制剂和ltb4受体拮抗剂的组合用于治疗炎症和疼痛的组合物
HK40028225B (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
hoon Lee The picture theory of eight pathways of COVID-19 in the real world
CN110496128A (zh) 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180105

Termination date: 20200128